Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(3 sites)
United States
Stanford University School of Medicine, Palo Alto, California Brigham and Women's Hospital, Boston, Massachusetts University of Virginia School of Medicine, Charlottesville, Virginia